Solentim will be exhibiting at Hanson Wades’s 5th Precision CRISPR Genome Editing Congress in Boston
Solentim, a global leader in cell line development instrumentation is pleased to announce it will be attending and exhibiting at the 5th Precision CRISPR Genome Editing Congress, 21st-23rd May, in Boston, USA
The conference will focus on the delivery of more precise, efficient and safer genome editing to optimise drug discovery, functional screening and CRISPR-based cell and gene therapies. With more than 100 thought leaders converging at the congress, it is a good opportunity to access the latest clinical data, define protocol best practice and gain insight into the future trends of CRISPR as the genetic engineering landscape rapidly continues to evolve.
Dr Ian Taylor, Chief Commercial Officer for Solentim, who will be attending the conference as a delegate, commented: “The Hanson Wade CRISPR Genome Editing Congress is a great forum to discuss the latest advances in CRISPR genome editing as well as related technologies and practices. We look forward to sharing how Solentim’s single cell isolation and clonality documentation products can aid CRISPR gene editing workflows.”